Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Fractyl Health, Inc.

Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Fractyl Health Announces Closing of $23 Million Underwritten Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Fractyl Health Announces Proposed Public Offering
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita® Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Fractyl Health Presents New Data at the American Diabetes Association’s 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Fractyl Health Announces Positive Initial Clinical Results Demonstrating Weight Maintenance Following GLP-1 Discontinuation and Revita Procedure in First Patient of the REVEAL-1 Cohort
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Fractyl Health to Participate in the Upcoming December Conferences
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024
From Fractyl Health, Inc.
Via GlobeNewswire
Tickers GUTS
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.